Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis : a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
© The Author(s) 2023. Published by Oxford University Press on behalf of British Association of Dermatologists..
BACKGROUND: Most information on the comparative effectiveness and survival of methotrexate (MTX) and adalimumab (ADA) in the treatment of psoriasis is from randomized control trials and may not translate to the everyday clinical setting.
OBJECTIVES: To determine the real-world effectiveness and survival of MTX and ADA in patients with moderate-to-severe psoriasis registered in the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
METHODS: Eligible patients were registered in BADBIR, ≥ 16 years of age and receiving a first course of MTX or ADA between September 2007 and December 2021, with ≥ 6 months of follow-up. Effectiveness was defined as achieving an absolute Psoriasis Area and Severity Index (PASI) ≤ 2 reported ≥ 13 weeks after the treatment start date until the stop date. The average treatment effect (ATE) was estimated using inverse probability of treatment weighting with propensity score, including baseline covariates. ATE results were presented as risk ratios (RR). A flexible parametric model was used to estimate adjusted standardized average survival, defined as treatment discontinuation associated with ineffectiveness or the occurrence of adverse events (AEs) at 6, 12 and 24 months. Restricted mean survival time (RMST) at 2 years of treatment exposure was calculated.
RESULTS: In total, 6575 patients (median age 44 years; 44% female) were analysed; 2659 (40.4%) were prescribed MTX and 3916 (59.5%) ADA. The proportion of patients achieving PASI ≤ 2 was higher in the ADA cohort (77.4%) than in the MTX cohort (37.4%). ADA was more effective than MTX [RR 2.20, 95% confidence interval (CI) 1.98-2.45]. Overall survival associated with ineffectiveness or AEs was lower in the MTX cohort than in the ADA cohort at 6 months [survival estimate 69.7 (95% CI 67.9-71.5) vs. 90.6 (95% CI 89.8-91.4)], 1 year [survival estimate 52.5 (95% CI 50.4-54.8) vs. 80.6 (95% CI 79.5-81.8)] and 2 years [survival estimate 34.8 (95% CI 32.5-37.2) vs. 68.6 (95% CI 67.2-70.0)]. The difference in RMST (years) overall, or when stratified by ineffectiveness and AEs, was 0.53 (95% CI 0.49-0.58), 0.37 (95% CI 0.33-0.42) and 0.29 (95% CI 0.25-0.33), respectively.
CONCLUSIONS: Patients on ADA were twice as likely to be clear or nearly clear of psoriasis and were less likely to discontinue their medication than patients on MTX. Findings from this real-world cohort provide important information to aid clinicians managing patients with psoriasis.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:189 |
|---|---|
| Enthalten in: |
The British journal of dermatology - 189(2023), 3 vom: 24. Aug., Seite 271-278 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Alabas, Oras A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adalimumab |
|---|
| Anmerkungen: |
Date Completed 30.08.2023 Date Revised 30.08.2023 published: Print CommentIn: Br J Dermatol. 2023 Jul 09;:. - PMID 37421659 Citation Status MEDLINE |
|---|
| doi: |
10.1093/bjd/ljad179 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357293010 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357293010 | ||
| 003 | DE-627 | ||
| 005 | 20231226072252.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/bjd/ljad179 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1190.xml |
| 035 | |a (DE-627)NLM357293010 | ||
| 035 | |a (NLM)37226927 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Alabas, Oras A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis |b a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.08.2023 | ||
| 500 | |a Date Revised 30.08.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Br J Dermatol. 2023 Jul 09;:. - PMID 37421659 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of British Association of Dermatologists. | ||
| 520 | |a BACKGROUND: Most information on the comparative effectiveness and survival of methotrexate (MTX) and adalimumab (ADA) in the treatment of psoriasis is from randomized control trials and may not translate to the everyday clinical setting | ||
| 520 | |a OBJECTIVES: To determine the real-world effectiveness and survival of MTX and ADA in patients with moderate-to-severe psoriasis registered in the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) | ||
| 520 | |a METHODS: Eligible patients were registered in BADBIR, ≥ 16 years of age and receiving a first course of MTX or ADA between September 2007 and December 2021, with ≥ 6 months of follow-up. Effectiveness was defined as achieving an absolute Psoriasis Area and Severity Index (PASI) ≤ 2 reported ≥ 13 weeks after the treatment start date until the stop date. The average treatment effect (ATE) was estimated using inverse probability of treatment weighting with propensity score, including baseline covariates. ATE results were presented as risk ratios (RR). A flexible parametric model was used to estimate adjusted standardized average survival, defined as treatment discontinuation associated with ineffectiveness or the occurrence of adverse events (AEs) at 6, 12 and 24 months. Restricted mean survival time (RMST) at 2 years of treatment exposure was calculated | ||
| 520 | |a RESULTS: In total, 6575 patients (median age 44 years; 44% female) were analysed; 2659 (40.4%) were prescribed MTX and 3916 (59.5%) ADA. The proportion of patients achieving PASI ≤ 2 was higher in the ADA cohort (77.4%) than in the MTX cohort (37.4%). ADA was more effective than MTX [RR 2.20, 95% confidence interval (CI) 1.98-2.45]. Overall survival associated with ineffectiveness or AEs was lower in the MTX cohort than in the ADA cohort at 6 months [survival estimate 69.7 (95% CI 67.9-71.5) vs. 90.6 (95% CI 89.8-91.4)], 1 year [survival estimate 52.5 (95% CI 50.4-54.8) vs. 80.6 (95% CI 79.5-81.8)] and 2 years [survival estimate 34.8 (95% CI 32.5-37.2) vs. 68.6 (95% CI 67.2-70.0)]. The difference in RMST (years) overall, or when stratified by ineffectiveness and AEs, was 0.53 (95% CI 0.49-0.58), 0.37 (95% CI 0.33-0.42) and 0.29 (95% CI 0.25-0.33), respectively | ||
| 520 | |a CONCLUSIONS: Patients on ADA were twice as likely to be clear or nearly clear of psoriasis and were less likely to discontinue their medication than patients on MTX. Findings from this real-world cohort provide important information to aid clinicians managing patients with psoriasis | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Adalimumab |2 NLM | |
| 650 | 7 | |a FYS6T7F842 |2 NLM | |
| 650 | 7 | |a Adjuvants, Immunologic |2 NLM | |
| 650 | 7 | |a Biological Factors |2 NLM | |
| 650 | 7 | |a Biological Products |2 NLM | |
| 650 | 7 | |a Etanercept |2 NLM | |
| 650 | 7 | |a OP401G7OJC |2 NLM | |
| 650 | 7 | |a Immunologic Factors |2 NLM | |
| 650 | 7 | |a Methotrexate |2 NLM | |
| 650 | 7 | |a YL5FZ2Y5U1 |2 NLM | |
| 700 | 1 | |a Mason, Kayleigh J |e verfasserin |4 aut | |
| 700 | 1 | |a Yiu, Zenas Z N |e verfasserin |4 aut | |
| 700 | 1 | |a Warren, Richard B |e verfasserin |4 aut | |
| 700 | 1 | |a Lunt, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Catherine H |e verfasserin |4 aut | |
| 700 | 1 | |a Griffiths, Christopher E M |e verfasserin |4 aut | |
| 700 | 0 | |a BADBIR Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Barker, Jonathan |e investigator |4 oth | |
| 700 | 1 | |a Morrison, Simon |e investigator |4 oth | |
| 700 | 1 | |a Bewley, Anthony |e investigator |4 oth | |
| 700 | 1 | |a Evans, Ian |e investigator |4 oth | |
| 700 | 1 | |a Griffiths, Christopher |e investigator |4 oth | |
| 700 | 1 | |a Ahmed, Shehnaz |e investigator |4 oth | |
| 700 | 1 | |a Kirby, Brian |e investigator |4 oth | |
| 700 | 1 | |a Kleyn, Elise |e investigator |4 oth | |
| 700 | 1 | |a Laws, Philip |e investigator |4 oth | |
| 700 | 1 | |a Hampton, Philip |e investigator |4 oth | |
| 700 | 1 | |a Alabas, Oras |e investigator |4 oth | |
| 700 | 1 | |a McElhone, Kathleen |e investigator |4 oth | |
| 700 | 1 | |a Yiu, Zenas |e investigator |4 oth | |
| 700 | 1 | |a Mackenzie, Teena |e investigator |4 oth | |
| 700 | 1 | |a McPherson, Tess |e investigator |4 oth | |
| 700 | 1 | |a Murphy, Ruth |e investigator |4 oth | |
| 700 | 1 | |a Ormerod, Anthony |e investigator |4 oth | |
| 700 | 1 | |a Walton, Shernaz |e investigator |4 oth | |
| 700 | 1 | |a Reynolds, Nick |e investigator |4 oth | |
| 700 | 1 | |a Smith, Catherine |e investigator |4 oth | |
| 700 | 1 | |a Warren, Richard |e investigator |4 oth | |
| 700 | 1 | |a Weller, Richard |e investigator |4 oth | |
| 700 | 1 | |a Gupta, Girish |e investigator |4 oth | |
| 700 | 1 | |a Zietemann, Vera |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The British journal of dermatology |d 1951 |g 189(2023), 3 vom: 24. Aug., Seite 271-278 |w (DE-627)NLM000000361 |x 1365-2133 |7 nnns |
| 773 | 1 | 8 | |g volume:189 |g year:2023 |g number:3 |g day:24 |g month:08 |g pages:271-278 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/bjd/ljad179 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 189 |j 2023 |e 3 |b 24 |c 08 |h 271-278 | ||